If you or a loved one has been prescribed Tysabri, you may have concerns about the risk of Progressive Multifocal Leukoencephalopathy (PML). This page provides a clear overview of the FDA's warning, who is at higher risk, and the recommended monitoring schedule. As part of a long-standing tradition of providing balanced medical information, we aim to help you make informed decisions about your health.
Tysabri (natalizumab) is a monoclonal antibody approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the risk is elevated in Tysabri-treated patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in patients receiving Tysabri: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to consider these factors in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. The FDA Adverse Event Reporting System (FAERS) data for Tysabri list fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and mobility decreased among the most frequently reported adverse events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports are not specific to PML, they reflect the types of neurological symptoms that may be associated with the condition.
The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri blocks the adhesion of leukocytes to endothelial cells, thereby reducing immune surveillance in the central nervous system. This immunosuppressive effect can allow reactivation of latent JC virus, leading to PML. The risk is particularly pronounced in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus. For patients who develop PML after Tysabri treatment, the timeline between exposure and documented harm can vary. PML may occur after months to years of therapy, with risk increasing after two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early recognition is critical, and the prescribing information instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). From a legal perspective, patients in Illinois who have been harmed by Tysabri-associated PML may have claims related to inadequate warnings. The boxed warning and prescribing information do describe the risk of PML and the known risk factors, but questions can arise about whether the warnings were sufficiently clear or timely, especially for patients who developed PML before the risk was fully characterized.
Attorney considerations for affected patients include the statute of limitations for filing a product liability lawsuit in Illinois. In Illinois, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or should have been discovered. For PML, this date may be when the diagnosis was confirmed or when symptoms first appeared. Patients should consult with an attorney promptly to ensure their claim is filed within the applicable time frame. The adequacy of warnings is a central issue in such cases. The prescribing information states that Tysabri increases the risk of PML and identifies three risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients may argue that the warnings did not adequately convey the severity or likelihood of PML, or that the risk was not properly communicated to them before treatment. The TOUCH Prescribing Program is designed to ensure that patients are informed of the risk, but compliance with the program does not necessarily eliminate liability if the warnings are found to be insufficient.
In summary, Tysabri is associated with a well-documented risk of PML, which can lead to severe disability or death. Patients in Illinois who have developed PML after Tysabri treatment should be aware of the statute of limitations for filing a claim and should seek legal counsel to evaluate the adequacy of the warnings they received. The medical evidence supports that PML is a known adverse effect of Tysabri, with risk factors including anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use. References - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962 - https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
In Illinois, the statute of limitations for personal injury claims, including those related to Tysabri-associated PML, is generally two years from the date the injury was discovered or should have been discovered. For PML, this date may be when the diagnosis was confirmed or when symptoms first appeared. It is crucial to consult with an attorney promptly to ensure your claim is filed within this timeframe.
Three factors are known to increase the risk of PML in patients receiving Tysabri: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals consider these factors when initiating and continuing treatment.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.